CERVOMED INC. - COMMON STOCK

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

01 أبريل 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed to Participate in Upcoming Investor Conferences

28 مارس 2024 16:05:00 بحسب Nasdaq GlobeNewswire

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

28 مارس 2024 08:30:00 بحسب Nasdaq GlobeNewswire

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

05 مارس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed to Participate in the BIO CEO and Investor Conference

21 فبراير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

12 فبراير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

07 فبراير 2024 08:30:00 بحسب Nasdaq GlobeNewswire

CervoMed to Participate in the Emerging Growth Conference 67

05 فبراير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

CervoMed to Participate in the Emerging Growth Conference 66

05 يناير 2024 08:00:00 بحسب Nasdaq GlobeNewswire